In June 2026, the academic salon on “Precision Treatment and Emerging Ablation Technologies,” supported by Hangzhou Ruidi Biotechnology Ltd., was successfully held at the Department of Ultrasound Medicine, Zhongshan Hospital, Fudan University in Shanghai. The event brought together leading experts in radiology and interventional oncology from the United States, Thailand, Vietnam, and other countries, focusing on the clinical application, research innovation, and international collaboration pathways of nanosecond pulsed electric field (nsPEF) ablation technology.
Global Experts Gather to Advance Precision Ablation
The salon was chaired by Professor XU Huixiong, Director of the Department of Ultrasound Medicine at Zhongshan Hospital. In his opening remarks, Prof. XU extended a warm welcome to the international delegates and emphasized that novel energy platforms, represented by Ruidi’s independently developed nsPEF system, are introducing new clinical paradigms and therapeutic approaches for minimally invasive tumor treatment.
The distinguished faculty included Prof. David C. Madoff from Yale School of Medicine, a globally recognized leader in interventional oncology, President-Elect of the World Ablation Association, Fellow of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE), Fellow of the American College of Radiology (ACR), and a founding member of the Society of Interventional Oncology (SIO). His pioneering work in preoperative portal vein embolization for hepatocellular carcinoma has significantly enhanced the safety of major liver surgeries worldwide. Also in attendance were Dr. Jirawadee Yodying from Bangkok Hospital, Thailand, and Dr. Artthaporn Ajalasereewong from the National Cancer Institute, Thailand, both of whom have long-standing expertise in interventional radiology clinical practice, education, and research, sharing practical insights from Southeast Asia. In addition, Dr. LE Nguyet Minh, Head of the Diagnostic Imaging and Interventional Radiology Center at Tam Anh Hospital, Vietnam, a senior expert in breast disease diagnosis and interventional therapy, offered innovative perspectives and clinical experiences from the region.
Ruidi’s nsPEF Technology Draws International Attention
During the academic exchange, participants engaged in in-depth discussions on the latest progress in nsPEF technology. Multiple experts noted that the Ruidi nsPEF system, with its distinctive advantages, including non-thermal effects, tissue-selective ablation, and immune microenvironment activation, demonstrates significant potential in the treatment of solid tumors.
Drawing on clinical cases from several European hospitals, the panel systematically reviewed the system’s application in complex scenarios such as high-risk hepatic hilar tumors and lesions adjacent to major vessels. The experts highly commended Ruidi’s nsPEF system for its continued improvements in safety, ease of operation, and intraoperative visualization. In-depth conversations also explored the synergistic development of AI-guided navigation, surgical robotics, and multi-modal image fusion, generating multiple actionable technical enhancements with strong potential for clinical translation.
Deepening International Collaboration for the Next Phase of nsPEF Development
This academic salon established an effective platform for dialogue between Ruidi Biotech and world-class interventional ultrasound teams. Initial consensus was reached on technology iteration, clinical research, and international multi‑center trials, laying a solid foundation for future collaboration.
Looking ahead, Ruidi Biotech remains committed to advancing nsPEF technology, leveraging its unique advantages in non-thermal effects, tissue-selective ablation, and immune microenvironment activation. We will continue to drive miniaturization and intelligent system upgrades, lowering the technical barriers and expanding clinical accessibility. Working in close synergy with global clinical experts, we aim to accelerate multi-center prospective studies, broaden the indications for nsPEF in high-risk solid tumors, and transition this technology from “exploratory frontier” to “clinical standard.” We firmly believe that nanosecond pulse ablation will become a cornerstone of precision oncology, offering new hope for patients worldwide.
